<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Galano-Frutos JJ</submitter><funding>Gobierno de Aragon</funding><funding>JPIAMR</funding><funding>Ministerio de Ciencia e Innovación</funding><funding>MICINN</funding><pagination>e27982</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11059415</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(7)</volume><pubmed_abstract>&lt;h4>Objectives&lt;/h4>The rise of antibiotic-resistant &lt;i>Streptococcus pneumoniae&lt;/i> (&lt;i>Sp&lt;/i>) poses a significant global health threat, urging the quest for novel antimicrobial solutions. We have discovered that the human hormone l-thyroxine has antibacterial properties. In order to explore its drugability we perform here the characterization of a series of l-thyroxine analogues and describe the structural determinants influencing their antibacterial efficacy.&lt;h4>Method&lt;/h4>We performed a high-throughput screening of a library of compounds approved for use in humans, complemented with ITC assays on purified &lt;i>Sp&lt;/i>-flavodoxin, to pinpoint molecules binding to this protein. Antimicrobial &lt;i>in vitro&lt;/i> susceptibility assays of the hit compound (l-thyroxine) as well as of 13 l-thyroxine</pubmed_abstract><journal>Heliyon</journal><pubmed_title>L-Thyroxine and L-thyroxine-based antimicrobials against Streptococcus pneumoniae and other Gram-positive bacteria.</pubmed_title><pmcid>PMC11059415</pmcid><funding_grant_id>PID2022-141068NB-I00</funding_grant_id><funding_grant_id>PID2019-107293 GB-I00</funding_grant_id><funding_grant_id>E45_23R</funding_grant_id><pubmed_authors>Schaible UE</pubmed_authors><pubmed_authors>Iguarbe V</pubmed_authors><pubmed_authors>Mamat U</pubmed_authors><pubmed_authors>Ainsa JA</pubmed_authors><pubmed_authors>Sancho J</pubmed_authors><pubmed_authors>Maity R</pubmed_authors><pubmed_authors>Galano-Frutos JJ</pubmed_authors><pubmed_authors>Velazquez-Campoy A</pubmed_authors></additional><is_claimable>false</is_claimable><name>L-Thyroxine and L-thyroxine-based antimicrobials against Streptococcus pneumoniae and other Gram-positive bacteria.</name><description>&lt;h4>Objectives&lt;/h4>The rise of antibiotic-resistant &lt;i>Streptococcus pneumoniae&lt;/i> (&lt;i>Sp&lt;/i>) poses a significant global health threat, urging the quest for novel antimicrobial solutions. We have discovered that the human hormone l-thyroxine has antibacterial properties. In order to explore its drugability we perform here the characterization of a series of l-thyroxine analogues and describe the structural determinants influencing their antibacterial efficacy.&lt;h4>Method&lt;/h4>We performed a high-throughput screening of a library of compounds approved for use in humans, complemented with ITC assays on purified &lt;i>Sp&lt;/i>-flavodoxin, to pinpoint molecules binding to this protein. Antimicrobial &lt;i>in vitro&lt;/i> susceptibility assays of the hit compound (l-thyroxine) as well as of 13 l-thyroxine</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Apr</publication><modification>2026-06-01T11:31:27.607Z</modification><creation>2026-04-08T11:52:48.237Z</creation></dates><accession>S-EPMC11059415</accession><cross_references><pubmed>38689973</pubmed><doi>10.1016/j.heliyon.2024.e27982</doi></cross_references></HashMap>